| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
REGULAR ARTICLES |
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Correspondence to Dr. Judith A. Miller, 11EN-221, The Toronto Hospital, General Division, 200 Elizabeth Street, Toronto, Ontario, Canada, M5G 2C4. Phone: 416-340-4966; Fax: 416-340-4951; E-mail: judith.miller{at}utoronto.ca
Abstract
Abstract. It has been demonstrated previously that moderate hyperglycemia without glucosuria can increase plasma renin activity and mean arterial pressure in young healthy males with early uncomplicated type 1 diabetes mellitus. This study was conducted to extend these observations by testing the hypothesis that mild to moderate hyperglycemia can affect renal function by increasing renin angiotensin system (RAS) activity in diabetic humans. The study included 10 men and women with early, uncomplicated type 1 diabetes (duration <5 yr), all ingesting a controlled sodium and protein diet. They were studied on four separate occasions, during a subdepressor dose of the angiotensin II (AngII) receptor blocker losartan, and during graded AngII infusion, 1.5 and 2.5 ng/kg per min, while euglycemic (blood glucose 4 to 6 mmol/L) and again while hyperglycemic without glucosuria (blood glucose 9 to 11 mmol/L), according to a randomized crossover design. Outcome measures included mean arterial pressure (MAP), GFR, effective renal plasma flow (ERPF), renal vascular resistance (RVR), filtration fraction (FF), and urine sodium excretion (UNaV) at baseline and in response to the above maneuvers. During hyperglycemic conditions, MAP was significantly higher compared with euglycemia, as were RVR and FF. After the administration of losartan, a significant renal and peripheral depressor effect was noted, with decreases in MAP, RVR, and FF, whereas during euglycemia the responses to losartan were minimal. AngII infusion resulted in elevations in MAP, RVR, and FF and a decline in UNaV during both glycemic phases, but the responses during hyperglycemia, most significantly at the 1.5 ng/kg per min infusion rate, were blunted. These data support the hypothesis that hyperglycemia affects renal function by activating the RAS. The mechanism remains obscure, but these contrasting responses may provide a link between the observations that maintenance of euglycemia and blockade of the RAS prevent or delay diabetic kidney disease, and furthermore, may clarify the mechanism whereby high glucose promotes renal disease progression in diabetes.
This article has been cited by other articles:
![]() |
A. Fekete, K. Rosta, L. Wagner, A. Prokai, P. Degrell, E. Ruzicska, E. Vegh, M. Toth, K. Ronai, K. Rusai, et al. Na+,K+-ATPase is modulated by angiotensin II in diabetic rat kidney - another reason for diabetic nephropathy? J. Physiol., November 15, 2008; 586(22): 5337 - 5348. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Sen, W. E. Rodriguez, N. Tyagi, M. Kumar, S. Kundu, and S. C. Tyagi Ciglitazone, a PPAR{gamma} agonist, ameliorates diabetic nephropathy in part through homocysteine clearance Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1205 - E1212. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Z. I. Cherney, J. W. Scholey, R. Nasrallah, M. G. Dekker, C. Slorach, T. J. Bradley, R. L. Hebert, E. B. Sochett, and J. A. Miller Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1336 - F1341. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Z.I. Cherney, J. A. Miller, J. W. Scholey, T. J. Bradley, C. Slorach, J. R. Curtis, M. G. Dekker, R. Nasrallah, R. L. Hebert, and E. B. Sochett The Effect of Cyclooxygenase-2 Inhibition on Renal Hemodynamic Function in Humans With Type 1 Diabetes Diabetes, March 1, 2008; 57(3): 688 - 695. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. C. Kopp, M. Z. Cicha, and M. A. Yorek Impaired responsiveness of renal sensory nerves in streptozotocin-treated rats and obese Zucker diabetic fatty rats: role of angiotensin Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R858 - R866. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. V. de Cavanagh, L. Ferder, J. E. Toblli, B. Piotrkowski, I. Stella, C. G. Fraga, and F. Inserra Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H456 - H465. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ahmed, I. B Aban, V. Vaccarino, D. M Lloyd-Jones, D. C Goff Jr, J. Zhao, T. E Love, C. Ritchie, F. Ovalle, G. Gambassi, et al. A propensity-matched study of the effect of diabetes on the natural history of heart failure: variations by sex and age Heart, December 1, 2007; 93(12): 1584 - 1590. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease Pharmacol. Rev., September 1, 2007; 59(3): 251 - 287. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D Stevanovic, N. D. Fisher, C. M Lansang, K. D Freeman, and N. K Hollenberg Short- and long-term glycaemic control and the state of the renin system in type 1 diabetes mellitus Journal of Renin-Angiotensin-Aldosterone System, June 1, 2007; 8(2): 85 - 92. [Abstract] [PDF] |
||||
![]() |
A. Kretowski, K. McFann, J. E. Hokanson, D. Maahs, G. Kinney, J. K. Snell-Bergeon, R. P. Wadwa, R. H. Eckel, L. Ogden, S. Garg, et al. Polymorphisms of the Renin-Angiotensin System Genes Predict Progression of Subclinical Coronary Atherosclerosis Diabetes, March 1, 2007; 56(3): 863 - 871. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Perlstein, M. Gerhard-Herman, N. K. Hollenberg, G. H. Williams, and A. Thomas Insulin Induces Renal Vasodilation, Increases Plasma Renin Activity, and Sensitizes the Renal Vasculature to Angiotensin Receptor Blockade in Healthy Subjects J. Am. Soc. Nephrol., March 1, 2007; 18(3): 944 - 951. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Bell, G. F. DiBona, Y. Wang, and M. W. Brands Mechanisms for Renal Blood Flow Control Early in Diabetes as Revealed by Chronic Flow Measurement and Transfer Function Analysis J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2184 - 2192. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. MacIsaac, S. Panagiotopoulos, K. J. McNeil, T. J. Smith, C. Tsalamandris, H. Hao, P. G. Matthews, M. C. Thomas, D. A. Power, and G. Jerums Is Nonalbuminuric Renal Insufficiency in Type 2 Diabetes Related to an Increase in Intrarenal Vascular Disease? Diabetes Care, July 1, 2006; 29(7): 1560 - 1566. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. Sochett, D. Z.I. Cherney, J. R. Curtis, M. G. Dekker, J. W. Scholey, and J. A. Miller Impact of Renin Angiotensin System Modulation on the Hyperfiltration State in Type 1 Diabetes J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1703 - 1709. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Awad, L. Huang, H. Ye, E. T. A. Duong, W. K. Bolton, J. Linden, and M. D. Okusa Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy Am J Physiol Renal Physiol, April 1, 2006; 290(4): F828 - F837. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Coppey, E. P. Davidson, T. W. Rinehart, J. S. Gellett, C. L. Oltman, D. D. Lund, and M. A. Yorek ACE Inhibitor or Angiotensin II Receptor Antagonist Attenuates Diabetic Neuropathy in Streptozotocin-Induced Diabetic Rats Diabetes, February 1, 2006; 55(2): 341 - 348. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Hakam, A. H. Siddiqui, and T. Hussain Renal angiotensin II AT2 receptors promote natriuresis in streptozotocin-induced diabetic rats Am J Physiol Renal Physiol, February 1, 2006; 290(2): F503 - F508. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Weekers, B. Bouhanick, S. Hadjadj, Y. Gallois, R. Roussel, F. Pean, A. Ankotche, G. Chatellier, F. Alhenc-Gelas, P. J. Lefebvre, et al. Modulation of the Renal Response to ACE Inhibition by ACE Insertion/Deletion Polymorphism During Hyperglycemia in Normotensive, Normoalbuminuric Type 1 Diabetic Patients Diabetes, October 1, 2005; 54(10): 2961 - 2967. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Thomas, C. Tikellis, W. M. Burns, K. Bialkowski, Z. Cao, M. T. Coughlan, K. Jandeleit-Dahm, M. E. Cooper, and J. M. Forbes Interactions between Renin Angiotensin System and Advanced Glycation in the Kidney J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2976 - 2984. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Ahmed, P. Hovind, H.-H. Parving, P. Rossing, D. A. Price, L. M. Laffel, M. C. Lansang, R. Stevanovic, N. D.L. Fisher, and N. K. Hollenberg Oral Contraceptives, Angiotensin-Dependent Renal Vasoconstriction, and Risk of Diabetic Nephropathy Diabetes Care, August 1, 2005; 28(8): 1988 - 1994. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Jacobsen Preventing end stage renal disease in diabetic patients -- genetic aspect (part I) Journal of Renin-Angiotensin-Aldosterone System, March 1, 2005; 6(1): 1 - 14. [Abstract] [PDF] |
||||
![]() |
H. S. Lim, R. J. MacFadyen, and G. Y. H. Lip Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart Arch Intern Med, September 13, 2004; 164(16): 1737 - 1748. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zeng, H. Xu, T.-L. Chew, R. Chisholm, M. M. Sadeghi, Y. S. Kanwar, and F. R. Danesh Simvastatin Modulates Angiotensin II Signaling Pathway by Preventing Rac1-Mediated Upregulation of p27 J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1711 - 1720. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Marwaha, A. A. Banday, and M. F. Lokhandwala Reduced renal dopamine D1 receptor function in streptozotocin-induced diabetic rats Am J Physiol Renal Physiol, March 1, 2004; 286(3): F451 - F457. [Abstract] [Full Text] |
||||
![]() |
S. Arima and S. Ito The mechanisms underlying altered vascular resistance of glomerular afferent and efferent arterioles in diabetic nephropathy Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1966 - 1969. [Full Text] [PDF] |
||||
![]() |
O. Torffvit Hyperglycaemia in diabetes: impact on nephropathy and cardiac risk Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1711 - 1715. [Full Text] [PDF] |
||||
![]() |
J. A. Miller, J. R. Curtis, and E. B. Sochett Relationship Between Diurnal Blood Pressure, Renal Hemodynamic Function, and the Renin-Angiotensin System in Type 1 Diabetes Diabetes, July 1, 2003; 52(7): 1806 - 1811. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Andersen, P. Jacobsen, L. Tarnow, P. Rossing, T. R. Juhl, and H.-H. Parving Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy Nephrol. Dial. Transplant., February 1, 2003; 18(2): 293 - 297. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Taniwaki, E. Ishimura, T. Kawagishi, N. Matsumoto, M. Hosoi, M. Emoto, T. Shoji, S. Shoji, T. Nakatani, M. Inaba, et al. Intrarenal Hemodynamic Changes After Captopril Test in Patients With Type 2 Diabetes: A duplex Doppler sonography study Diabetes Care, January 1, 2003; 26(1): 132 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
M C. Lansang, S. Y Osei, C. Coletti, J. Krupinski, and N. K Hollenberg Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 19 - 23. [Abstract] [PDF] |
||||
![]() |
M. Chidambaram, J. A. Duncan, V. S. Lai, D. C. Cattran, J. S. Floras, J. W. Scholey, and J. A. Miller Variation in the Renin Angiotensin System throughout the Normal Menstrual Cycle J. Am. Soc. Nephrol., February 1, 2002; 13(2): 446 - 452. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Tuttle, M. E. Puhlman, S. K. Cooney, and R. A. Short Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes Am J Physiol Renal Physiol, January 1, 2002; 282(1): F103 - F112. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Kang, J. A. Duncan, D. C. Cattran, J. S. Floras, V. Lai, J. W. Scholey, and J. A. Miller Effect of oral contraceptives on the renin angiotensin system and renal function Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2001; 280(3): R807 - R813. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Wehbi, J. Zimpelmann, R. M. Carey, D. Z. Levine, and K. D. Burns Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors Am J Physiol Renal Physiol, February 1, 2001; 280(2): F254 - F265. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Fitzgerald and M. W. Brands Nitric oxide may be required to prevent hypertension at the onset of diabetes Am J Physiol Endocrinol Metab, October 1, 2000; 279(4): E762 - E768. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Osei, D. A. Price, L. M. B. Laffel, M. C. Lansang, and N. K. Hollenberg Effect of Angiotensin II Antagonist Eprosartan on Hyperglycemia-Induced Activation of Intrarenal Renin-Angiotensin System in Healthy Humans Hypertension, July 1, 2000; 36(1): 122 - 126. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673